1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease-Reference-Cited by-同舟云学术

1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease

Published:2015-02-24 Issue:8 Volume:93 Page:1267-1278
ISSN:0360-4012
Container-title:Journal of Neuroscience Research
language:en
Short-container-title:Journal of Neuroscience Research

Author:

Chung Jin Yong¹,Lee Ji Won¹,Ryu Choon Ho¹,Min Hye Kyung¹,Yoon Yeo Jin¹,Lim Mi Jung¹,Park Cheol Hyoung¹

Affiliation:

1. Drug Discovery Center; SK Biopharmaceuticals Ltd.; Dae Jeon South Korea

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jnr.23577/fullpdf

Reference78 articles.

1. CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice;Airavaara;Cell Transplant,2000

2. Cognitive, affective, and psychiatric features of Parkinson's disease;Barbas;Clin Geriatr Med,2006

3. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression;Bespalova;Eur J Pharmacol,2008

4. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse;Bezard;Eur J Neurosci,2000

5. Study 016 Investigators. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations;Borgohain;Mov Disord,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safinamide alleviates hyperalgesia via inhibiting hyperexcitability of DRG neurons in a mouse model of Parkinson's disease;Behavioural Brain Research;2024-02

2. Mood disturbances in Parkinson's disease: From prodromal origins to application of animal models;Neurobiology of Disease;2023-06

3. Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence;Current Neuropharmacology;2023-03

4. Application of Neurotoxin-Induced Animal Models in the Study of Parkinson’s Disease-Related Depression: Profile and Proposal;Frontiers in Aging Neuroscience;2022-05-13

5. Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinson’s Disease;NeuroPsychopharmacotherapy;2022